103 results
Page 2 of 6
8-K
EX-99.1
ms4cf5rwtrpar1tv45vc
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
yy6ugzl0ahd
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
dxtu2eol1luz is
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
c2vjbd4ybj5tohado
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
858nun
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
dss2s1
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRE 14A
2z6an pv5
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-99.1
y8kp8qk
3 Apr 23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:17pm
8-K
EX-99.1
45b8yjqfoml84m
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
d8c670
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
w6a6d12wwstw
29 Mar 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
k84sd e1tevq4wghnomv
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
868801z92
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm